Themis Medicare Reports Declining Sales and Profitability in March 2025 Results
Themis Medicare has reported its financial results for the quarter ending March 2025, revealing a decline in net sales to Rs 71.70 crore and a negative profit before tax of Rs -12.68 crore. The operating profit margin has dropped to -8.08%, with earnings per share at Rs -1.05.
Themis Medicare, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's financial health, as reflected in the evaluation changes. The score has seen a revision, moving to -19 from -15 over the past three months.The financial data reveals several concerning trends. Net sales for the quarter stood at Rs 71.70 crore, marking a significant decline compared to the average of Rs 107.91 crore over the previous four quarters. This downturn in sales is accompanied by a profit before tax less other income (PBT) of Rs -12.68 crore, which is considerably lower than the average PBT of Rs 13.84 crore from the prior quarters. Similarly, profit after tax (PAT) has also fallen sharply to Rs -9.66 crore, contrasting with an average PAT of Rs 11.53 crore.
Additionally, the company's operating profit margin has reached its lowest point at -8.08%, indicating challenges in operational efficiency. The earnings per share (EPS) have also declined to Rs -1.05, reflecting a decrease in profitability for shareholders. While non-operating income has increased to Rs 1.55 crore, its sustainability remains uncertain.
For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
